Skip to main content

Advertisement

Log in

Treatment of Multifocal Motor Neuropathy

  • NEUROMUSCULAR DISORDERS (SR RUDNICKI, SECTION EDITOR)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Multifocal motor neuropathy (MMN) is a treatable immune disorder of the peripheral nerves that is characterized clinically by slowly progressive or stepwise asymmetric distal > proximal, upper > lower limb weakness in multiple motor nerve distributions; electrophysiologically by multifocal motor demyelination, specifically partial motor conduction block; laboratory evidence of high serum anti-GM1 IgM antibodies; and remarkable treatment response to intravenous immunoglobulin (IVIG). IVIG has become the treatment of choice, and the U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid 10 % [immune globulin infusion (human)] as a treatment for multifocal motor neuropathy (MMN). Response to IVIG in MMN is dose- and frequency-dependent, most patients needing high (2 g/kg) and frequent (every 4–8 weeks) doses for several years. Over time, response to IVIG may decrease despite higher and more frequent dosing of IVIG treatment. Subcutaneous immunoglobulin (dose equivalent to IVIG) given in weekly fashion has recently been used with equal efficacy and fewer side effects. There are some case reports and non-randomized trials suggesting variable results from therapeutic or adjunctive use of other immunosuppressive or immunomodulatory agents such as cyclophosphamide, cyclosporine, methotrexate, azathioprine, interferon beta-1a, and rituximab. Of these, cyclophosphamide and rituximab are the only immune treatments that have shown some benefits in case reports. One randomized controlled trial of mycophenolate mofetil used as adjunctive agent did not prove efficacious in altering the disease course. Although MMN, like chronic inflammatory demyelinating polyneuropathy (CIDP), is a chronic immune-mediated demyelinating neuropathy, the use of corticosteroids and plasma exchange – two other therapies used in CIDP – is not beneficial for MMN. Further investigations are warranted to evaluate the immunopathogenesis of MMN and to explore options for dose, frequency, and duration of IVIG treatment as well as the use of alternative immunomodulatory agents either as primary therapeutic or adjunctive agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References and Recommended Reading

  1. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–80.

    Article  PubMed  Google Scholar 

  2. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve. 2000;23:900–8.

    Article  CAS  PubMed  Google Scholar 

  3. Pringle CE, Belden J, Veitch JE, Brown WF. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve. 1997;20:347–51.

    Article  CAS  PubMed  Google Scholar 

  4. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies /Peripheral Nerve Societies guideline on management of multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:295–301.

    Article  Google Scholar 

  5. Chaudhry V, Corse AM, et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve. 1994;17:198–205.

    Article  CAS  PubMed  Google Scholar 

  6. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001;124:145–53.

    Article  PubMed  Google Scholar 

  7. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75:1961–7. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB.

    Article  CAS  PubMed  Google Scholar 

  8. Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol. 2000;48:919–26.

    Article  PubMed  Google Scholar 

  9. Delmont E, Azulay JP, Giorgi R, Attarian S, Verschueren A, Uzenot D, et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology. 2006;67:592–6.

    Article  CAS  PubMed  Google Scholar 

  10. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibodies and intravenous immunoglobulin for rheumatic diseases: rationale and mechanism of action. Nat Clin Pract Rheumatol. 2007;3:262–72.

    Article  CAS  PubMed  Google Scholar 

  11. Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM mediated complement deposition in MMN. J Neuroimmunol. 2010;229:256–62.

    Article  CAS  PubMed  Google Scholar 

  12. Yuki N, Watanabe H, Nakajima T, Spaeth PJ. IVIg blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82:87–91.

    Article  CAS  PubMed  Google Scholar 

  13. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–9.

    Article  PubMed  Google Scholar 

  14. Nobile-Orazio E, Gallia F. Multifocal motor neuropathy: current therapies and novel strategies. Drugs. 2013;73(5):397–406

    Google Scholar 

  15. Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.

    Article  CAS  PubMed  Google Scholar 

  16. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single-blinded cross-over trial. Eur J Neurol. 2009;16:631–8.

    Article  CAS  PubMed  Google Scholar 

  17. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies–a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.

    Article  CAS  PubMed  Google Scholar 

  18. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–9.

    Article  CAS  PubMed  Google Scholar 

  19. Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10.

    Article  PubMed  Google Scholar 

  20. Chaudhry V, Corse A, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33:237–42.

    Article  CAS  PubMed  Google Scholar 

  21. Pestronk A, Cornblath DR, Ilyas A, et al. A treatable multi-focal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.

    Article  CAS  PubMed  Google Scholar 

  22. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991;30:397–401.

    Article  CAS  PubMed  Google Scholar 

  23. Pestronk A, Florence J, Miller T, et al. Treatment of IgM associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–9.

    Article  CAS  PubMed  Google Scholar 

  24. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178–9.

    Article  PubMed  Google Scholar 

  25. Stielgbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromuscul Disord. 2009;19:473–5.

    Article  Google Scholar 

  26. Michaud A, Delmont E, Jeandel PY, Desnuelle C. Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab (in French). Rev Neurol (Paris). 2011;167:916–20.

    Article  CAS  Google Scholar 

  27. Rojas-Garcia R, Gallardo E, de Andrés I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61:1814–6.

    Article  CAS  PubMed  Google Scholar 

  28. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35:66–9.

    Article  CAS  PubMed  Google Scholar 

  29. Chaudhry V, Cornblath DR. An open label trial of rituximab (Rituxan_) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196–201.

    Article  CAS  PubMed  Google Scholar 

  30. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68(24 Suppl 4):S8–S11.

    Article  CAS  PubMed  Google Scholar 

  31. Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferon: biological effects, mechanism of action and use in multiple sclerosis. Ann Neurol. 1995;37:7–15.

    Article  CAS  PubMed  Google Scholar 

  32. Martina ISJ, van Doorn PA, Schmitz PIM, et al. Chronic motor neuropathies: response to interferon-b1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry. 1999;66:197–201.

    Article  CAS  PubMed  Google Scholar 

  33. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-b1A. Neurology. 2000;54:1518–21.

    Article  PubMed  Google Scholar 

  34. Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst. 2009;14:201–2.

    Article  PubMed  Google Scholar 

  35. Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990;40(1):118–27.

    Article  CAS  PubMed  Google Scholar 

  36. Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol. 2003;250:1118–20.

    Article  PubMed  Google Scholar 

  37. Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84–91.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Vinay Chaudhry has served as secretary for the American Board of Electrodiagnostic Medicine, has served as a consultant for Novartis, has provided expert testimony for the Department of Health and Human Services, has received honoraria for serving on the editorial board for Neurologist, and has held a patent on the Total Neuropathy Score.

Madhavi Jinka declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vinay Chaudhry MD.

Additional information

This article is part of the Topical Collection on Neuromuscular Disorders

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jinka, M., Chaudhry, V. Treatment of Multifocal Motor Neuropathy. Curr Treat Options Neurol 16, 269 (2014). https://doi.org/10.1007/s11940-013-0269-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-013-0269-y

Keywords

Navigation